Clinical Trials

NCT IdNCT04834024
TitleMIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma
ConditionFollicular Lymphoma and Marginal Zone Lymphoma
OrganizationBeijing Mabworks Biotech Co., Ltd.
Sponsor/CollaboratorsBeijing Mabworks Biotech Co., Ltd.
StatusNot yet recruiting
Older Adult
Location (with distance)
DescriptionThis phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.